Free Trial

Pressure BioSciences Q1 2023 Earnings Report

Pressure BioSciences logo
$0.0025 0.00 (0.00%)
(As of 12/20/2024 05:55 PM ET)

Pressure BioSciences EPS Results

Actual EPS
-$0.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pressure BioSciences Revenue Results

Actual Revenue
$0.74 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pressure BioSciences Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

Pressure BioSciences Earnings Headlines

This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
The big blood pressure experiment
See More Pressure BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pressure BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pressure BioSciences and other key companies, straight to your email.

About Pressure BioSciences

Pressure BioSciences (OTCMKTS:PBIO) develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.

View Pressure BioSciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings